Fig. 1

Study design. Participants repeatedly responded to questionnaires which detailed their prescribed medications. We used these responses to identify all participants not using lipid-regulating drugs between 2001–2010 (‘baseline’) then split these participants into cases and controls based on whether they reported taking prescribed lipid-regulating drugs from 2014–2019 (‘follow-up’). A subset of participants (n = 766) had transcriptomic data profiled from punch biopsies which included adipose tissue from this baseline period. We compared a catalogue of 103 clinical traits at baseline, 88 trajectories in these traits between baseline and follow-up, and gene expression from adipose tissue samples at baseline for future users of lipid-regulating drug versus controls. Figure adapted from “Double-Blinded, Randomized, Placebo-Controlled, Crossover Study (Graphical, 1)” by BioRender.com (2020). Retrieved from these templates: https://app.biorender.com/biorender-templates.